// App-Quantinova.ai

: Glycogen synthase kinase-3 (GSK-3) inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: Implications for anti-PD-1 immunotherapy

Researchers

Presenter

  • Christopher E. Rudd

Principal Investigators

  • Janna Krueger

  • Alison Taylor

Medical Centers

  • Centre de Recherche Hôpital Maisonneuve-Rosemont, Universite de Montreal, Canada

  • Univ. of Montreal, Canada

  • Leeds Institute of Cancer and Pathology Wellcome Trust Brenner Building Level 5 University of Leeds, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Melanoma

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 8A

  • Granzyme B

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved